Granulocyte-Macrophage Colony-Stimulating Factor and Vasculitis
Authors: Robert Dreicer
Journal: Annals of Internal Medicine (1989)

Letters and Corrections1 July 1989Granulocyte-Macrophage Colony-Stimulating Factor and VasculitisRobert Dreicer, MD, MS, Joan H. Schiller, MD, Paul P. Carbone, MDRobert Dreicer, MD, MSSearch for more papers by this author, Joan H. Schiller, MDSearch for more papers by this author, Paul P. Carbone, MDSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-111-1-91_2 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the Editor: Recombinant granulocyte-macrophage colony-stimulating factor (rGM-CSF) is now being widely used in clinical trials. Reported toxic effects include fever, nausea and vomiting, bone pain, and fluid retention (1, 2). We report a case of exacerbated vasculitis in a patient with small-cell lung cancer who presented with a paraneoplastic vasculitis. The patient was treated with chemotherapy and rGM-CSF.A 52-year-old man presented with cough, arthralgia, myalgia, and a rash on his thighs. A skin biopsy specimen showed leukocytoclastic vasculitis. Urinalysis was positive for occult blood and 1+ protein; serum creatinine was 88.4 µmol/L (1.0 mg/dL); Wintrobe sedimentation rate was...References1. Vadhan-RajKeatingLeMaistre SMA. Effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes. N Engl J Med. 1987;317:1545-52. CrossrefMedlineGoogle Scholar2. BrandtPetersAtwater SWS. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on hematopoietic reconstitution after high-dose chemotherapy and autologous bone marrow transplantation. N Engl J Med. 1988;318:869-76. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: University of Wisconsin—Madison Medical School Madison, WI 53792 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byCutaneous adverse reactions to drugsThe coexistence of Sweet's syndrome and Still's disease—is it merely a coincidence?Cutaneous and Systemic Manifestations of Drug-Induced VasculitisDRUG-INDUCED VASCULITESCrucial Role of Donor‐Derived Stromal Cells in Successful Treatment for Intractable Autoimmune Diseases in MRL/lpr Mice by BMT Via Portal VeinGranulocyte-macrophage colony-stimulating factor (GM-CSF) but not granulocyte colony-stimulating factor (G-CSF) induces plasma membrane expression of proteinase 3 (PR3) on neutrophils in vitroParaneoplastic rheumatic syndromesSweet’s syndrome accompanying leukaemia: seven cases and review of the literatureVasculitides secondary to systemic diseasesGranulocyte colony-stimulating factor treatment for cyclophosphamide-induced severe neutropenia in Wegener's granulomatosisBullous Pyoderma Gangrenosum in a Patient with Myelodysplastic Syndrome During Granulocyte Colony-Stimulating Factor TherapySweet's syndrome induced by granulocyte colony-stimulating factor in a woman with congenital neutropeniaRecombinant Human Interleukin-3 Induces Extramedullary Hematopoiesis at Subcutaneous Injection Sites in Cynomolgus MonkeysA generalized cutaneous reaction induced by granulocyte colony-stimulating factorCutaneous reactions to recombinant cytokine therapyUnusual cutaneous manifestations of myelodysplastic syndromeReactivation of rheumatoid arthritis and development of leukocytoclastic vasculitis in a patient receiving granulocyte colony-stimulating factor for felty's syndromeFelty's syndrome treated with rhG-CSF associated with flare of arthritis and skin rashNecrotizing vasculitis and exacerbation of psoriasis after granulocyte colony-stimulating factor for small cell lung carcinomaSweet's syndrome associated with G-CSFSouthwestern Internal Medicine Conference: Clinical Use of Hematopoietic Growth FactorsExacerbation of psoriasis with GM-CSF therapyAcute arterial thrombosis after escalated-dose methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy with recombinant granulocyte colony-stimulating factor: A possible new recombinant granulocyte colony-stimulating factor toxicityThe Sweet Syndrome during Therapy with Granulocyte Colony-stimulating FactorJohn W. Park, MD, Bhoomi Mehrotra, MD, Bryan O. Barnett, MD, Ari D. Baron, MD, Alan P. Venook, MDBullous pyoderma gangrenosum after granulocyte colony-stimulating factor treatmentColony-stimulating factorsPolynucléoses neutrophiles d'origine systémique ou bactérienne: valeur discriminante de la C Réactive Protéine?Blood and blood products 1 July 1989Volume 111, Issue 1Page: 91-92KeywordsCreatinineFeversGranulocyte macrophage colony stimulating factorLung and intrathoracic tumorsMyalgiaNauseaRashesSerum proteinsVasculitisVomiting Issue Published: 1 July 1989 PDF downloadLoading ...